TY  - JOUR
AU  - Smolen, Josef S.
AU  - Kremer, Joel M.
AU  - Gaich, Carol L.
AU  - DeLozier, Amy M.
AU  - Schlichting, Douglas E.
AU  - Xie, Li
AU  - Stoykov, Ivaylo
AU  - Rooney, Terence
AU  - Bird, Paul
AU  - Sanchez Burson, Juan Miguel
AU  - Genovese, Mark C.
AU  - Combe, Bernard
PY  - 2017
DO  - 10.1136/annrheumdis-2016-209821
SN  - 0003-4967
UR  - http://hdl.handle.net/10668/19029
T2  - Annals of the rheumatic diseases
AB  - Objectives To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to >= 1 tumour necrosis factor inhibitors (TNFis) or other...
LA  - en
PB  - Bmj publishing group
KW  - Quality-of-life
KW  - Necrosis-factor inhibitors
KW  - Disease-activity
KW  - Clinical-trials
KW  - Methotrexate
KW  - Improvement
KW  - Therapy
KW  - Questionnaire
KW  - Tofacitinib
KW  - Abatacept
TI  - Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
TY  - research article
VL  - 76
ER  -